Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study
- PMID: 39414772
- PMCID: PMC11484707
- DOI: 10.1038/s41408-024-01164-x
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study
Conflict of interest statement
HM: Advisory Board/Consultancy- Janssen, BMS, Pfizer, Takeda, Sanofi, Abbvie; Research Funding: Janssen, Pfizer. AV: Advisory board: Janssen, Forus therapeutics, Sanofi, Pfizer; Research funding: Janssen. GM: Payments for writing from MashupMD. Research funding to institution: Janssen. SA: Advisory/Consultancy: Janssen, Pfizer, Sanofi. RC: Advisory/Consultancy: Janssen, Sanofi, Adaptive.
Figures
References
-
- Royce CS, Hayes MM, Schwartzstein RM. Teaching critical thinking: a case for instruction in cognitive biases to reduce diagnostic errors and improve patient safety. Acad Med. 2019;94:187–94. - PubMed
-
- Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19:e305–e316. - PubMed
-
- ICES, Mission, Vision and Values. 2022. https://www.ices.on.ca/About-ICES/Mission-vision-and-values
Publication types
LinkOut - more resources
Full Text Sources
